VCI Wealth Management’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$3.27M Buy
12,506
+3,370
+37% +$864K 0.78% 35
2026
Q2
$2.3M Buy
+9,136
New +$1.97M 0.58% 49
2026
Q1
– Sell
-12,008
Closed -$2.74M – 124
2025
Q4
$2.74M Buy
+12,008
New +$2.74M 0.76% 31
2025
Q3
– Sell
-9,028
Closed -$1.68M – 116
2025
Q2
$1.68M Buy
9,028
+1,414
+19% +$263K 0.59% 41
2025
Q1
$1.6M Buy
+7,614
New +$1.48M 0.67% 34

Other funds holding ABBV

VCI Wealth Management's ABBV Position: Q3 2026 in Review

VCI Wealth Management increased its AbbVie (ABBV) stake by 37% in Q3 2026, buying an estimated $864K and bringing the position to 12,506 shares worth $3.27M. The position accounts for 0.78% of the portfolio, ranked #35.

VCI Wealth Management first reported a position in ABBV in Q1 2025 and has held it in 5 quarters since. 2,287 funds tracked by Wall St. Rank hold ABBV as of Q3 2026.

  • VCI Wealth Management held 12,506 shares of AbbVie worth $3.27M as of Q3 2026.
  • VCI Wealth Management bought 3,370 AbbVie shares in Q3 2026, an estimated $864K.
  • AbbVie made up 0.78% of VCI Wealth Management's portfolio in Q3 2026, its #35 holding.
  • VCI Wealth Management first reported a position in AbbVie in Q1 2025 and has held it in 5 quarters since.
  • 2,287 funds tracked by Wall St. Rank held AbbVie as of Q3 2026.

Based on VCI Wealth Management's 13F filing for Q3 2026, filed 29 Oct 2026.